Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
-
-
-
-
Amandine Desette, Pierre-Olivier Guichet, Sheik Emambux, Konstantin Masliantsev, Ulrich Cortes, et al.. Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16 (5), pp.757-782. ⟨10.1016/j.jcmgh.2023.07.008⟩. ⟨hal-04302791⟩
-
Mots clés
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Body mass index
Histiocytosis
BRAFV600-mutant melanoma
Circulating tumor DNA
Brain Metastases
Colorectal cancer
Diagnosis
Prevention
Wnt
AZD9291
BRAF V600-mutation
Biomarker
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Systemic therapy
Radiotherapy
Bariatric surgery
Acute generalized exanthematous pustulosis
Allelic imbalance
Prognostic
Targeted therapy
Antibody-drug conjugate
Resistance
Colon cancer
Merkel cell carcinoma
Adjuvant FOLFOX
Non-small cell lung cancer
Surgical excision
Treatment
Chemotherapy
Crizotinib
Anti-CTLA-4
Cancer bronchique non à petites cellules
Locally advanced
Biomarkers
C797S
Adverse events
BRAF
Lung adenocarcinoma
Sonic Hedgehog
Bone marrow niche
Immunohistochemistry
2-chlorodeoxyadenosine
Melanoma
Invasive cutaneous squamous cell carcinoma
Beta-catenin
Plasma
Nivolumab
Anti-PD-1
Dabrafenib
Follow-up
Adjuvant
AML
Children
ADN tumoral circulant
Anti-PD1
TNM classification
Langerhans cell histiocytosis
Prognosis
Abdominal pain
Colorectal carcinoma
BRAF V600E
ALK rearrangement
ACTH
CARMN
Metastatic
Anti-PD-1 antibody
BRAFV600E mutation
Advanced melanoma
EGFR
Polyomavirus
Metastatic cSCC
Osimertinib
Immunomodulation
Circulating cell-free DNA
Anti-Tumor pharmacology
Advanced
Molecular targeted therapies
ALK
Biliopancreatic diversion
Mesenchymal stromal cells
Cancer
Immunotherapy
Cemiplimab
Anti-PD1 blockade
Immune checkpoint inhibitor
Androgen insensitivity
Gastric bypass
Antineoplastic agents
Radiofrequency ablation
Trametinib
Cutaneous squamous cell carcinoma
Staging
Safety
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Survival
Abscopal effect
Adjuvant therapy
BRAFV600E
Chemoresistance